The Relevance of Preclinical Models to the Treatment of Postmenopausal Breast Cancer

Oncology (Switzerland)

Volumn 54, Issue 2, 1997, Pages 6-10

  Dukes, M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Anastrozole; Animal models; Pharmacokinetics; Preclinical models

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ANASTROZOLE; ANDROSTENEDIONE; AROMATASE; AROMATASE INHIBITOR; ESTROGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CANCER; CANCER GROWTH; CONFERENCE PAPER; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SCREENING; ENZYME ACTIVITY; ESTROGEN SYNTHESIS; FEEDBACK SYSTEM; FEMALE; HUMAN; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; OVULATION; POSITIVE FEEDBACK; POSTMENOPAUSE; PRIORITY JOURNAL; UTERUS DISEASE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; NITRILES; POSTMENOPAUSE; RATS; TRIAZOLES;

EID: 0030690027     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227748     Document Type: Article

References (8)

1. Simpson ER, Mahcndroo MS, Means GD, Kilgore MW, Corbin CJ, Mendclson CR: Tissue-specific promotors regulate aromatase cytochrome P450 expression. J Steroid Biochem Mol Biol 1993;44:321-330.
2. Yates RA, Dowsett M, Fisher GV, Selcn A, Wyld PJ: Arimidex (ZD1033): A selective, potent inhibitor of aromatase in post-menopausal female volunteers. Br J Cancer 1996;73:543-548.
3. Santen RJ: Potential clinical role of new aromatase inhibitors. Steroids 1987;50:575-593.
4. Daniel SAJ, Armstrong DT: Enhancement of folliclc-stimulating-hormonc induced aromatase activity by androgens in cultured rat granulosa cells. Endocrinology 1980; 107:1027-1033.
5. Brodie AMH, Brodic HJ, Garrett WM, Hendrickson JR, Marsh DA, Tsai-Morris C-H: Effect of an aromatase inhibitor, 1,46-androsta-trienc-3,17-dione, on 7,12-dimethylbcnz[a]an-thraccnc-induccd mammary tumours in the rat and its mechanism of action in vivo. Biochem Pharmacol 1982;31:2017-2023.
6. Dukes M, Edwards PN, Large M, Smith IK, Boyle T: The preclinical pharmacology of ‘Arimidex’ (anastrozole: ZD 1033) - A potent, selective aromatase inhibitor. J Steroid Biochem Mol Biol 1996;58:439-445.
7. Plourde PV, Dyroff M, Dukes M: Arimidex (TM): A potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994;30:103-111.
8. Gcislcr J, King N, Dowsett M, Ottestad L, Lundgrcn S, Walton P, Kormcset PO, Lonning PE: Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74:1286-1291.